Truist Securities Reaffirms Its Buy Rating for Teva Pharmaceutical Industries Limited (TEVA)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is one of the 12 Best Widow and Orphan Stocks to Buy According to Analysts.

On September 23, 2025, Truist Securities reaffirmed its Buy rating for Teva Pharmaceutical Industries Limited (NYSE:TEVA), maintaining its $25 price target, following a recap call on Olanzapine LAI (long-acting injectable) data presented at the Psychiatric Congress. Truist emphasized the potential of Teva’s schizophrenia treatment franchise based on the new data.

The launch of Olanzapine LAI is part of Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s broader strategy to expand its innovative medicines division, which grew 27% in Q2 to offset a slight decline in generics.

CEO Richard Francis highlighted Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s transition toward higher-value treatments during the Bank of America Global Healthcare Conference on September 24, where he reiterated the company’s focus on innovation, debt reduction, and achieving $700 million in cost savings by 2027. Key drugs such as Austedo are projected to reach $3 billion in peak sales, while Ajovy could generate up to $2 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, manufactures, markets, and distributes generic and biopharmaceutical products across the U.S., Europe, Israel, and other countries. It is one of the Best Widow and Orphan Stocks.

While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 14 Best IT Stocks to Buy for the Long Term.

Disclosure: None.